White House Drops Plan to Politicize NIH Grant Funding After Senate Pushback

In late September 2026 the White House halted a draft executive order that would have created an external board with veto power over National Institutes of Health (NIH) grant awards. The board, slated to include Office of Management and Budget (OMB) Director Russell Vought and NIH Director Jay Bhattacharya, was intended to align biomedical research funding with President Donald Trump’s policy priorities. After opposition from Republican Senate Appropriations Chair Susan Collins and bipartisan members of Congress, officials said the order would not move forward.

WXLV - Winston-SalemThe HillThe HillDaily BeastNewsweek

The NIH disburses roughly $48 billion annually to studies of cancer, infectious disease and other priorities. Grants are awarded after a peer-review process mandated by Congress. Earlier in the Trump administration, OMB proposed a rule expanding political review of federal health grants; that rule was temporarily blocked by a continuing-resolution provision signed on September 2, 2026. The current proposal was seen as a revival of that effort, aimed in part at curbing funding for institutions the president labeled “woke,” notably Harvard University.

The Hill

• NIH’s annual budget: $48 billion.

WXLV - Winston-Salem

• 174 NIH-affiliated scientists have won Nobel Prizes.

The Hill

Senator Collins wrote to OMB Director Vought and NIH Director Bhattacharya, urging the administration to abandon the plan and submit any reforms through legislation. She emphasized that the peer-review system “is key to NIH’s success.”

The Hill

White House officials declined comment on the draft order, while OMB representatives confirmed the proposal was no longer being pursued.

The Hill

Both Democratic and Republican lawmakers criticized the plan as an attempt to inject ideology into research funding. Senator Patty Murray warned that a single political appointee could halt a cancer study or an Alzheimer’s trial without scientific justification. Advocacy group Research! America said a political committee would slow medical research and jeopardize ongoing clinical trials.

Semafor

Some outlets reported the White House had merely “backed away,” suggesting the administration might still seek other mechanisms to increase oversight. Other reports, including Politico and The Hill, stated unequivocally that the executive order had been dropped. The precise status of any alternative drafting effort remains unclear, as no official confirmation has been issued.

Politico

• “Your proposal to establish a new committee to review NIH grants risks undermining the Congressionally-mandated peer review process that all NIH grants must undergo before they are approved for federal funding,” — Sen. Susan Collins

The Hill

• “We should not have a politicized process for awarding research and biomedical grants to institutions. It needs to be merit-based, and I’m glad that the White House listened to those of us who were making that argument,” — Sen. Susan Collins

The Hill

• “Whether lifesaving medical research gets funded or not should be determined by experts at the NIH, not a panel of lackeys chosen by Donald Trump and Russ Vought,” — Sen. Patty Murray

Newsweek

The continuing resolution that passed Congress on September 2, 2026 blocks any rule or executive action similar to the proposed board through December 11, 2026. Lawmakers will monitor the administration’s next steps on NIH oversight during this window.

Politico